Sensei Biotherapeutics, Inc. · NASDAQ:SNSE
Sensei Biotherapeutics — JP Morgan Healthcare Conference 2022
33 slides from Sensei Biotherapeutics's conference presentation, Jan 10, 2022
Slide 1: Training the Immune System to Fight Cancer
Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer JP Morgan Healthcare Conference January 10, 2022 NASDAQ: SNSE August © 2021 Sensei Biotherapeutics. All rights reserved.
Slide 2: Disclaimer
This presentation has been prepared by Sensei Biotherapeutics, Inc. (the “Company,” “we,” “us”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as o
Slide 3: The Modern-Day Challenge in Immuno-Oncology
The Modern-Day Challenge in Immuno-Oncology Majority of patients don’t respond to PD- Global PD-1/PD-L1 Market2 1/PD-L1 monotherapy1 2 1. . Market Gerber estimates et al., Biochemical from PD -Pharmacology 1 and PDL-1 Inhibitors 2016 Market Size in 2021 – MarketWatch, 360 Research
Slide 4: Two Major Types of Non-Responders to PD-1 Blockade
Two Major Types of Non-Responders to PD-1 Blockade Responders T-cells Inside Tumor Non-Responders T-cells Inactive or T-cells Absent Outside Tumor Green = T-cells Purple = tumor Adapted from Van der Woulde-LL, et al, Trends in Cancer, 2017
Slide 5: Two Platforms to Unleash Anti-Cancer T-cell Activity
Two Platforms to Unleash Anti-Cancer T-cell Activity TMAb™ (Tumor Microenvironment Activated Biologics) Platform Next-generation tumor activated mAbs Binding only in the low-pH tumor microenvironment Target checkpoints and/or other immune pathways Enable improved PK/PD and toxicity profiles ImmunoPh
Slide 6: T-Cells Are Central to Our Approach
T-Cells Are Central to Our Approach and the Key to Unlocking Groundbreaking Clinical Activity Focus on novel immune checkpoints to UNLEASH anti-tumor T-cells Focus on multi-antigen approach to GENERATE anti-tumor T-cells
Slide 7: Positioned to Drive Value with Next Generation Product & Platform Development
Positioned to Drive Value with Next Generation Product & Platform Development Two Platforms Pipeline Provide Opportunities Broad TMAb* ImmunoP Platform ™ Platfor manufacturing In-house GMP capabilities Strong Cash Position Ended 3Q 2021: $156.7M** Business Development **Consists *Tumor Microenvironm
Slide 8: Pipeline Utilizing Pioneering ImmunoPhage Platform, TMAb Platform
Pipeline Utilizing Pioneering ImmunoPhage Platform, TMAb Platform Program Phase 1 / 2 Indication Discovery IND-enabling (Target) Clinical SNS-101 Solid Tumors (VISTA) SNS-102 Solid Tumors (VSIG4) SNS-103 Solid Tumors (ENTPDase1/CD39) Merkel Cell Carcinoma Head and Neck Cancer SNS-401-NG (Multiple Tu
Slide 9: TMAb (Tumor Microenvironment Activated biologics) Platform
TMAb (Tumor Microenvironment Activated biologics) Platform
Slide 10: pH-sensitive Antibodies Selectively Bind Targets in the Low-pH Tumor Microenvironment
pH-sensitive Antibodies Selectively Bind Their Targets in the Low-pH Tumor Microenvironment TMAb PLATFORM The tumor microenvironment of pH ~6 is lower than physiological pH of 7.4 Sensei’s technology identifies pH-sensitive antibodies that bind only at the tumor Antibodies that bind at physiological
Slide 11: The Promise and Challenge of Immunotherapy
The Promise and Challenge of Immunotherapy Targeting Immunosuppressive myeloid cells is a promising strategy to overcome resistance to checkpoint Inhibitor therapy THE PROMISE Using the body’s own immune system to attack cancer Capitalizing on immunological specificity and long-term memory Achieving
Slide 12: VISTA: An Emerging Checkpoint Target on Myeloid Cells
VISTA: An Emerging Checkpoint Target on Myeloid Cells Target Overview: Large market opportunity B7 family ligand Extensive expression on myeloid cells1 Inhibition of VISTA may lead to activation of myeloid cells Excellent therapeutic combinability with CTLA-4 or PD-1/PD-L1 ICIs, especially in cold t
Slide 13: Increased Understanding of VISTA as a Promising Target
Increased Understanding of VISTA as a Promising Target to Address the Needs of Patients with Cancer I IU H COMM U N I CA TIO N S VlSlA i) au inltibitory inuuune cht:ckpoint that is increased after !pUimum:1b therapy in patients With prostatt cancer
Slide 14: VISTA Checkpoint is Activated at the Low pH of the Tumor Microenvironment
VISTA Checkpoint is Activated at the Low pH of the Tumor Microenvironment Antibodies that block protonated VISTA histidines interrupt PSGL-1 binding1 1. Johnston et al., Nature 2019 VISTA’s extracellular domain is uniquely rich in histidines¹ Histidines are protonated at low pH enabling VISTA to dis
Slide 15: Key to Unlocking the Power of VISTA
Key to Unlocking the Power of VISTA 1. Block the pH-dependent binding of VISTA to PSGL-1 on T cells at low pH 2. Selectively bind VISTA at low pH to avoid: target mediated drug disposition (TMDD) on-target/off-tumor side effects 3. Utilize an Fc-competent IgG backbone to engage and activate FcƔR on
Slide 16: SNS-101 Inhibits Interaction of VISTA to PSGL-1 at Low pH
SNS-101 Inhibits Interaction of VISTA to its Receptor, PSGL-1, in CD4/CD8 T-Cells at Low pH 6.0 SNS-101: Fully human monoclonal antibody that selectively binds active (low pH) VISTA, but not inactive VISTA in the blood No significant binding to VISTA+ monocytes at pH 7.4 Potent inhibitor of PSGL-1 b
Slide 17: SNS-101 Has >600-Fold Selectivity for VISTA pH6
SNS-101 Has >600-Fold Selectivity for VISTApH6 Biophysical characterization demonstrates >600-fold selectivity for VISTA at pH 6.0 Picomolar binding at low pH No significant binding observed at physiological pH (7.4) pH 6.0 pH 7.4 132 Monovalent Affinity (KD) [nM] 0.218 (~No binding) SITC 2021: Post
Slide 18: Proposed Mechanism of Action for SNS-101
Proposed Mechanism of Action for SNS-101 Fc-competent framework is required for optimal activity, but FcÆ”R engagement in the blood may result in untoward “off tumor” activation (i.e. CRS) Non-pH dependent pH-dependent
Slide 19: SNS-101 Is a Differentiated Anti-VISTA Antibody
SNS-101 Is a Differentiated Anti-VISTA Antibody TMAb Platform K01401-020; SNS-101 VISTA.18 KVA12.1 CI-8993; JNJ-61610588 HMBD-002 W0180 (BMS) (Kineta) (J&J/Curis) (Hummingbird) (Pierre Fabre) Inhibit PSGL-1 Yes Yes unknown Yes unknown unknown Binding pH Sensitive Yes Yes No No No No Binding Fc Activ
Slide 20: VSIG4: A Novel Next Generation Checkpoint
VSIG4: A Novel Next Generation Checkpoint Modulating the Tumor Microenvironment Second TMAb program B7 family related protein Expressed on macrophages Inhibits T-cell activation Novel therapeutic combinability with existing IO drugs No approved therapies against VSIG4 Adapted from Zang et al., J Cli
Slide 21: ImmunoPhage Platform
ImmunoPhage™ Platform
Slide 22: Bacteriophage
Bacteriophage Ubiquitous viruses that infect bacteria but not mammalian cells. Adept at activating the human immune system in multiple unique ways
Slide 23: Generating Strong Antibody and T-cell Responses
Generating Strong Antibody and T-cell Responses Immuno Phage Platform Bacteriophage virus is engineered and manufactured with both antigen and immune stimulatory viral DNA The Immuno Phage™ bacteriophage is an icosahedron with a tail. This configuration can be viewed as an activating signal to the i
Slide 24: Generating Strong Antibody and T-cell Responses
Generating Strong Antibody and T-cell Responses ImmunoPhages are taken-up by APCs and deliver three critical signals required to drive activation of T cells. Phage taken up by antigen presenting cells Antigen cross presentation Positive co-stimulation Generation of Th1-biased immune response & cytok
Slide 25: ImmunoPhage: A Multi-Pronged Approach to Address the Complexities of Cancer
ImmunoPhage™ A Multi-Pronged Approach to Address the Complexities of Cancer Our ImmunoPhages can mount a multi-modal attack on cancer, combining the benefits of a traditional vaccine with localized gene therapy Targeted therapeutic vaccine MHC-mediated immunity Bacteriophage have natural tropism for
Slide 26: SNS-401-NG: Building the First Custom Merkel Cell Polyoma Virus ImmunoPhage
SNS-401-NG: Building the First Custom Merkel Cell Polyoma Virus (MCPyV) ImmunoPhage SNS-401-NG Development Collaboration with University of Washington to build first custom Merkel Cell Carcinoma (MCC) vaccine cocktail consisting of Merkel Cell Polyoma Virus epitopes and other patient specific antige
Slide 27: SNS-401-NG Potential to be First Fully Customized, Yet Off-the-Shelf, Therapy
SNS-401-NG has Potential to be First Fully Customized, Yet Off-the-Shelf, Therapy SNS-401-NG Development in Merkle Cell Patients would receive a bespoke mixture of ImmunoPhage that included antigens from the MCPyV and a subset of TAA-expressing ImmunoPhage Immunophage expressing MCPyV+ MCPyV B- and
Slide 28: Phortress: Proprietary Library of Personalized Vaccine Cocktails
Phortress: Proprietary Library of Personalized Vaccine Cocktails with Off-the-Shelf ImmunoPhage “Ingredients” These “cocktails” are defined by the disease or patient genetics Combinations are customized to cover multiple epitopes, protein domains or targets Each ImmunoPhage is pre-manufactured to ta
Slide 29: Personalized Immunotherapy Approach Could Accelerate Speed to Treatment
Personalized Immunotherapy Approach Could Accelerate Speed to Treatment High speed and low cost-of-goods of ImmunoPhage allows a broader array of antigens Personalized yet Off-the Shelf TAA Therapy Off-the-Shelf + Patient-specific Neoantigen Therapy Routine Tumor Personalized yet Neoantigen Neoantig
Slide 30: Sensei's Vision to Capture Platform and Pipeline Value
Sensei’s Vision to Capture Platform and Pipeline Value Feb 2021: IPO Invest in Advanced first Manufacturing and program into clinic Supply Chain Measured Absorb key Focus on Commercial investments in learnings and Platform Capabilities platform refine Innovation and and Pipeline technology New INDs
Slide 31: Proven Team With Deep Experience
Proven Team With Deep Experience John Celebi, MBA President and CEO Robert Pierce, MD Chief R&D Officer Erin Colgan Chief Financial Officer Michael Boychyn, PhD VP, Technical Operations Elisabeth Colunio VP, Human Resources Edward van der Horst, PhD SVP, TMAb Antibodies auline Callinan, PhD P, Busin
Slide 32: Expected Program Milestones
Expected Program Milestones SNS-101 (anti-VISTA) 1H 2023: IND filing 2022: Publish data demonstrating preclinical profile SNS-401-NG 2H 2022: Initiate IND-enabling studies SNS-102 (anti-VSIG4) 2023: Select product candidate SNS-103 (anti-ENTPDase1/CD39) 2023: Select product candidate
Slide 33: Training the Immune System to Fight Cancer
Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer JP Morgan Healthcare Conference January 10, 2022 NASDAQ: SNSE © 2021 Sensei Biotherapeutics. All rights reserved.
Sensei Biotherapeutics — JP Morgan Healthcare Conference 2022 on 6ix